Overview
- Sanofi reported at the American Thoracic Society meeting in Orlando that efdoralprin alfa raised trough alpha‑1 antitrypsin by 24.1 micromolar at week 32 versus 7.6 micromolar with weekly plasma therapy.
- The 97-person ElevAATe study randomly assigned patients to efdoralprin alfa every three or four weeks or to the standard weekly plasma-derived infusion.
- Patients on the study drug kept protective AAT protein within the normal range throughout the trial, while those on standard care did so less than half the time.
- The therapy is made with recombinant technology, which could reduce reliance on donated plasma that limits supply for current treatments.
- The program remains experimental and unapproved after Phase 2, following Sanofi’s 2024 $2.2 billion purchase of the asset through its Inhibrx deal.